AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6413133
Drug: Branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain amino acid (BcAA) enriched parenteral nutrition
Trial: 23907163
Drug: Curriculum progression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Curriculum progression adjustments based on formative assessments (e.g. repeat lessons, skip lessons) every 4 weeks.
Trial: 20600032
Drug: Budesonide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (3 mg, three times daily or twice daily) + Azathioprine (1-2 mg/kg/d)
Trial: 20600032
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg/d, tapered to 10 mg/d) + Azathioprine (1-2 mg/kg/d)
Trial: 20600032
Drug: Budesonide (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (after 6 months of prednisone) + Azathioprine (1-2 mg/kg/d)
Trial: 12626350
Drug: Oral arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral arginine therapy
Trial: 10741622
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral nisoldipine with 200 mL grapefruit juice (G0)
Trial: 10741622
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral nisoldipine with 200 mL grapefruit juice (G14)
Trial: 10741622
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral nisoldipine with water (control)
Trial: 10741622
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral nisoldipine with water (G38)
Trial: 10741622
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral nisoldipine with water (G72)
Trial: 10741622
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral nisoldipine with water (G96)
Trial: 9015467
Drug: Ciprofibrate 100
RxNorm normalized name: ciprofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate 100 mg once daily
Trial: 7604800
Drug: Bezafibrate 400
RxNorm normalized name: bezafibrate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 400 mg once daily
Trial: 6352622
Drug: ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftazidime 2 g bd
Trial: 6352622
Drug: cefamandole 2
RxNorm normalized name: cefamandole 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefamandole 2 g tds and tobramycin 80 mg bd
Trial: 26164019
Drug: Calcitriol (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.025 μg) once daily for 14 days
Trial: 26164019
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily for 14 days
Trial: 23374729
Drug: 0.5% PRO2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% PRO2000 gel
Trial: 20851460
Drug: 2% PRO2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% PRO2000 gel
Trial: 15708255
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation (CF) radiotherapy, 2 Gy daily up to 60 Gy in 6 weeks
Trial: 11870157
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation therapy (64.8 Gy)
Trial: 11870157
Drug: Standard-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose radiation therapy (50.4 Gy)
Trial: 299220
Drug: T‐antigen immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T‐antigen immunotherapy combined with cytostatic therapy
Trial: 30607757
Drug: Culturally-adapted Cognitive
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally-adapted Cognitive Processing Therapy (CPT)
Trial: 21421179
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30 mg/d
Trial: 21421179
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 mg/d
Trial: 21421179
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 70 mg/d
Trial: 21421179
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) (all doses combined)
Trial: 15126920
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C (1g/day) and E (800 mg/day) for 8 consecutive days
Trial: 7632128
Drug: GH substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH substitution treatment
Trial: 332439
Drug: 26 mg
RxNorm normalized name: RNA 1.26 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 mg EACH
Trial: 332439
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg EACH
Trial: 332439
Drug: 33 mg
RxNorm normalized name: inulin 833 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33 mg EACH
Trial: 31125266
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with etoposide-cisplatin (EtoCis)
Trial: 23207373
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral controlled‐release morphine
Trial: 16621339
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus CM
Trial: 16621339
Drug: Sertraline-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline-only
Trial: 16621339
Drug: Sertraline conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline conditions
Trial: 10475180
Drug: Dalteparin (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (subcutaneous, twice daily for 3 months)
Trial: 8693440
Drug: Inhaled morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled morphine sulphate 1 mg/ml (5 ml)
Trial: 8693440
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (5 ml)
Trial: 18689559
Drug: 700 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 IU/day of supplemental vitamin D(3) and 500 mg/day of supplemental calcium
Trial: 15974900
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg; two 40 mg tablets once daily)
Trial: 1761666
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment with human menopausal gonadotrophin (HMG)
Trial: 29607625
Drug: Turmeric tonic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric tonic, administered twice a day for 9 weeks
Trial: 29607625
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered twice a day for 9 weeks
Trial: 25571684
Drug: Bifidobacterium bifidum
RxNorm normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium bifidum DN‐173 010 (1 x 10(10) cfu/g) in probiotic fruit yogurt, 110 g per day for 2 weeks
Trial: 25571684
Drug: Placebo fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo fruit yogurt, 110 g per day for 2 weeks
Trial: 16680620
Drug: Neurocognitive enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocognitive enhancement therapy (NET) + paid work therapy (WT)
Trial: 16680620
Drug: Paid work
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paid work therapy (WT)
Trial: 11940541
Drug: Enoxaparin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1.0 mg/kg subcutaneously every 12 hours +/- initial 30 mg intravenous bolus)
Trial: 11940541
Drug: Enoxaparin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.3 to 0.75 mg/kg subcutaneously every 12 hours +/- initial intravenous bolus of 30 mg)
Trial: 11940541
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH) (bolus 60 U/kg; infusion 12 U/kg per hour)
Trial: 11940541
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH) (bolus 40 U/kg; infusion 7 U/kg per hour)
Trial: 1914378
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg galanthamine hydrobromide intravenous infusion for 30 minutes
Trial: 1914378
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg galanthamine hydrobromide intravenous infusion for 30 minutes
Trial: 1914378
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg single oral dose of galanthamine
Trial: 6140230
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg metoprolol (beta‐1‐selective blockade)
Trial: 6140230
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg bupranolol (nonselective beta‐blockade)
Trial: 6140230
Drug: Both beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both beta-blockers (metoprolol and bupranolol)
Trial: 27860410
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg every 2 weeks
Trial: 26299550
Drug: Midazolam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2.5 mg)
Trial: 26299550
Drug: Midazolam-alfentanil combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-alfentanil combination (1 mg midazolam and 5 μg/kg alfentanil)
Trial: 26299550
Drug: Propofol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5 mg/kg intravenous bolus)
Trial: 25030782
Drug: High-fructose (HF)
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose (HF) sweetened beverage (710 mL/d, 50 g fructose/d, 15 g glucose/d)
Trial: 25030782
Drug: High-glucose (HG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-glucose (HG) sweetened beverage (710 mL/d, 50 g glucose/d, 15 g fructose/d)
Trial: 20033075
Drug: Aliskiren 150-300
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150-300 mg per day
Trial: 20033075
Drug: Ramipril 5-10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5-10 mg per day
Trial: 18005484
Drug: High-fibre meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fibre meal (HFM) (15 g of fibre)
Trial: 18005484
Drug: Low-fibre meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fibre meal (LFM) (3 g of fibre)
Trial: 12385542
Drug: Spironolactone 100
RxNorm normalized name: spironolactone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 100 mg orally once daily
Trial: 12385542
Drug: Spironolactone 100
RxNorm normalized name: spironolactone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 100 mg orally once daily with propranolol 40 mg orally twice daily
Trial: 1514500
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nifedipine
Trial: 28007005
Drug: 0.01% oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% oral capsaicin gel
Trial: 28007005
Drug: 0.025% oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% oral capsaicin gel
Trial: 21489699
Drug: 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/kg CRH infusion
Trial: 19407292
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 20 ml 0.5% bupivacaine (group 1)
Trial: 19407292
Drug: Portal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal infiltration of 20 ml 0.5% bupivacaine (group 2)
Trial: 12518376
Drug: L-asparaginase therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase therapy
Trial: 11063156
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg daily for 6 months
Trial: 9067278
Drug: Plasma folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma folate deficiency (<3 ng/ml)
Trial: 7933504
Drug: Buprenorphine suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine suppository (0.4 mg) preoperative administration (group A1)
Trial: 7933504
Drug: Buprenorphine suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine suppository (0.4 mg) postoperative administration (group A2)
Trial: 7933504
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 0.1 mg of buprenorphine during surgery and postoperative administration of buprenorphine suppository (group A3)
Trial: 28169080
Drug: music-plus-massage group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: music-plus-massage group (n=60) receiving a combination of their favorite songs and Swedish massage
Trial: 19393768
Drug: PPA administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA administration with educational module
Trial: 19393768
Drug: Initial explanation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial explanation and baseline PPA administration
Trial: 16905783
Drug: 3-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-drug regimen (Zidovudine/lamivudine plus efavirenz)
Trial: 16905783
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen (Zidovudine/lamivudine/abacavir plus efavirenz)
Trial: 16905783
Drug: 3-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-drug regimen
Trial: 15592270
Drug: Metronidazole 0.75%
RxNorm normalized name: METRONIDAZOLE 0.75% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.75% gel (37.5 mg metronidazole per dose), once nightly for 5 nights
Trial: 15592270
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg plus nystatin 100,000 U ovules, once nightly for 5 nights
Trial: 11485952
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate at a dose of 200 microg/day
Trial: 11485952
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate at doses of 100-250 microg/day
Trial: 11485952
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate at a dose of around 500 microg/day
Trial: 9441148
Drug: Induced labor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced labor (artificial rupture of membranes and oxytocin infusion)
Trial: 7964952
Drug: Five-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug regimen (etoposide, thioguanine, dexamethasone, daunorubicin, and cytarabine)
Trial: 7964952
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy consolidation
Trial: 2444802
Drug: Metoprolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (beta 1-selective antagonist)
Trial: 2444802
Drug: Labetalol (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (combined alpha/beta-receptor blockade)
Trial: 25539791
Drug: LY40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY40 mg BID
Trial: 25539791
Drug: LY80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY80 mg BID
Trial: 25539791
Drug: Risperidone (RIS)
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone (RIS) 2 mg BID
Trial: 20409331
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg Methylprednisolone + 10 mg Lidocaine
Trial: 20409331
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Methylprednisolone + 10 mg Lidocaine
Trial: 20409331
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline + 10 mg Lidocaine (placebo)
Trial: 18952164
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day vitamin C
Trial: 12717099
Drug: Allopurinol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (400 mg) administered orally just after admission (60 min before reperfusion)
Trial: 22102633
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no allopurinol treatment)
Trial: 12717099
Drug: Allopurinol treatment
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol treatment group
Trial: 9459673
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (15 sessions)
Trial: 8333258
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid viscous eye drops 1% given twice daily
Trial: 8333258
Drug: Chloramphenicol eye
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol eye drops 0.5% given 6 times daily
Trial: 3511401
Drug: High-dosage trihexyphenidyl
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage trihexyphenidyl (30 mg)
Trial: 30194737
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program plus 1% chlorhexidine varnish monthly application
Trial: 30194737
Drug: Current oral
RxNorm normalized name: black currant oil Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current oral hygiene practice (control)
Trial: 18947472
Drug: Control (pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pulse intravenous infusion of cyclophosphamide (CTX) plus prednisone)
Trial: 18947472
Drug: Control (pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pulse intravenous infusion of cyclophosphamide (CTX))
Trial: 12598347
Drug: Tamoxifen alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen alone (160 mg day 1, then 20 mg/day for 5 years)
Trial: 12598347
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus tamoxifen (20 mg/day for 5 years)
Trial: 30688410
Drug: Preprandial metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial metformin administration (500-1,000 mg)
Trial: 30688410
Drug: Postprandial metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial metformin administration (500-1,000 mg)
Trial: 25064164
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC) 100 mg/kg/dose administered every 6 hours until delivery
Trial: 25064164
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC) 100 mg/kg/dose
Trial: 25064164
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC) 12.5-25 mg/kg/dose administered every 12 hours for 5 doses
Trial: 25064164
Drug: Saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered within 4 hours of CA diagnosis
Trial: 17593161
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg daily for 12 weeks
Trial: 11943936
Drug: Desmopressin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (300 microg nasal inhalation)
Trial: 9951357
Drug: Intensive acupuncture
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive acupuncture treatment (25 sessions over 2 months, 30 minutes each)